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The function of PSMC5 (proteasome 26S subunit, ATPase 5) in tumors, particularly with respect to cancer
radioresistance, is not known. Here, we identiﬁed PSMC5 as a novel radiosensitivity biomarker,
demonstrating that radiosensitive H460 cells were converted to a radioresistance phenotype by PSMC5
depletion. Exposure of H460 cells to radiation induced a marked accumulation of cell death-promoting
reactive oxygen species, but this effect was blocked in radiation-treated H460 PSMC5-knockdown cells
through downregulation of the p53-p21 pathway. Interestingly, PSMC5 depletion in H460 cells enhanced
both AKT activation and MDM2 transcription, thereby promoting the degradation of p53 and p21 pro-
teins. Furthermore, speciﬁc inhibition of AKT with triciribine or knockdown of MDM2 with small
interfering RNA largely restored p21 expression in PSMC5-knockdown H460 cells. Our data suggest that
PSMC5 facilitates the damaging effects of radiation in radiation-responsive H460 cancer cells and
therefore may serve as a prognostic indicator for radiotherapy and molecular targeted therapy in lung
cancer patients.
© 2015 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Radiotherapy is commonly used to treat lung cancer, although it
can also damage normal cells. However, intrinsic and acquired
cellular radioresistance is a major impediment to improving the
survival rate of non-small cell lung cancer (NSCLC) patients [1].
Despite several preclinical and clinical trials designed to improve
the beneﬁcial effects of radiotherapy, themechanisms that promote
radioresistance in NSCLC have not been fully investigated. The
development and incorporation of molecular targeted ther-
apeuticsdthe most prominent recent advance in the cancer
research ﬁeld [2]dillustrates the potential synergy of radiation
combined with targeted therapy and underscores the need toer Biology, Korea Institute of
-gu, Seoul 01812, Republic of
Inc. This is an open access article uovercome radioresistance problems in lung cancer, particularly in
NSCLC patients.
The 26S proteasome is a multi-catalytic proteinase complex
consisting of the 20S core particle and a set of 19S regulatory
proteins [3]. Human PSMC5 (proteasome 26S subunit, ATPase 5),
also known as SUG1, TRIP1 (thyroid hormone receptor-interacting
protein 1) and TBP10 (Tat-binding protein homolog 10), among
others, is a 19S regulatory component that can recognize ubiquitin-
labeled proteins, converting them into a form suitable for degra-
dation by the 20S complex. In addition to participating in protea-
some function, PSMC5 is directly involved in regulating
mammalian transcription through its association with transcrip-
tionally active promotors and recruitment of coactivators. For
example, this subunit plays a critical role in MHC class II tran-
scription by regulating the activity of class II transactivator CIITA [4]
and in p53-mediated p21 transcription by recruiting p53 to the p21
promoter region in response to ultraviolet radiation-induced DNA
damage [5]. It has recently been reported that PSMC5 acts as a
critical effector in osteoblast disease by causing cytodifferentiationnder the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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ﬁbroblast trans-differentiation to a myoﬁbroblast phenotype [7].
However, the association and function of PSMC5 in tumors, espe-
cially in terms of cellular mechanisms related to radiotherapy
resistance, have not been explored.
In the present study, we report that PSMC5 knockdown in
radiosensitive H460 NSCLC cells enhanced the ability of these cells
to resist apoptosis in response to radiation. This acquisition of a
radioresistance phenotype was attributable to diminished reactive
oxygen species (ROS) generation through inhibition of p53-p21
signaling. The upstream signaling event in this action of PSMC5
depletion was induction of both AKT activation and MDM2
expression, which promoted p53-p21 protein degradation. There-
fore, we propose PSMC5 as a novel potential biomarker for mo-
lecular targeted therapeutic strategies in radioresistant lung cancer
patients.2. Materials and methods
2.1. Cell culture and treatment
Human H460 cells were purchased from ATCC (Manassas, VA,
USA). A radioresistant derivative (RR-H460) was established from
H460 cells as described previously [8]. Cells were cultured in RPMI-
1640 medium containing 10% fetal bovine serum. Cells were irra-
diated using a 137Cs-ray source (Atomic Energy of Canada, Ltd.,
Mississauga, Canada) at a dose rate of 3.81 Gy/min and treated with
10 mM triciribine (Calbiochem, San Diego, CA, USA) to inhibit AKT
activity.2.2. Gel electrophoresis and mass spectrometry analysis
Parental H460 and RR-H460 cell lines were solubilized in 200 ml
of polyacrylamide gel electrophoresis buffer (9 M urea, 40 mM Tris,
4% CHAPS, pH 8.5), disrupted with a probe sonicator (Branson Ul-
trasonic Corporation, Danbury, USA), and centrifuged at 12000 rpm
for 15 min. Cell lysates (150 mg) were resolved by two-dimensional
polyacrylamide gel electrophoresis (2-D PAGE) as described pre-
viously [8]. All protein spots in gels were visualized using the silver
staining method and then digested with 10 ng/mL trypsin (Prom-
ega, Madison, WI, USA). Dried tryptic peptides were analyzed by
mass spectrometry, and proteins were identiﬁed by peptide mass
ﬁngerprinting as described previously [8].2.3. Oncomine data mining
Oncomine (Life Technologies, Ann Arbor, MI, USA) was used for
data analysis and visualization as described previously [9]. PSMC5
expression was compared in lung cancer and normal lung tissue
extracts.2.4. Immunohistochemistry
Human tissue microarrays were purchased from SuperBioChips
(Cat Number: CC5; Seoul, Korea), and immunohistochemistry was
performed using an anti-PSMC5 mouse monoclonal antibody
(1:250 dilution; Santa Cruz Biotechnology Inc., Santa Cruz, CA, USA)
as described previously [10]. Immunostaining was performed using
the avidin-biotin-peroxidase method according to the manufac-
turer's instructions (Invitrogen, Carlsbad, CA, USA). Staining in-
tensity was scored as follows: 0 (no visible staining), 1 þ (faint
staining), 2 þ (moderate staining), and 3 þ (strong staining).2.5. Quantitative reverse transcription-polymerase chain reaction
(qRT-PCR)
Transcripts were quantiﬁed by qRT-PCR as described previously
[8] using the following primer pairs: PSMC5 (150-bp product), 50-
AGA ATG GTG AGG GAG CTG TT-30 (sense) and 50-GTT GAG CAA CTC
CAG CAT CG-30 (antisense); p53 (361-bp product), 50-GTG GTG CCC
TAT GAG CCG CC-30 (sense) and 50-GCT CAC GCC CAC GGATCT GA-30
(antisense); p21 (74-bp product), 50-GGC AGA CCA GCA TGA CAG
ATT-30 (sense) and 50-GCG GAT TAG GGC TTC CTC T-30 (antisense);
MDM2 (259-bp), 50-AAG ACT ATT CTC AGC CAT CA-30 (sense) and
50-CAT ACT GGG CAG GGC TTA-30 (antisense); and glyceraldehyde-
3-phosphate dehydrogenase (GAPDH; 305-bp product), 50-CAT CTC
TGC CCC CTC TGC TGA-30 (sense) and 50-GGA TGA CCT TGC CCA CAG
CCT-30 (antisense).2.6. Cell death assay
Cell death was quantiﬁed as described previously [8]. Apoptotic
cell death was also determined by Western blot analysis of cleaved
poly (ADP-ribose) polymerase (PARP) and activated caspase-3.2.7. Colony-forming assay
Cell survival was determined by clonogenic survival assays, as
described previously [8]. Brieﬂy, cells were seeded into triplicate
60-mm tissue culture dishes at densities of 1.2, 6.0, and 12.0  103
cells/dish and exposed to 0, 4, and 6 Gy radiation, respectively. Cells
were exposed once to the indicated doses of radiation. After 14 d,
colonies arising from surviving cells were stained with trypan blue
solution and counted using a colony counter (Imaging Products,
Chantilly, VA, USA).2.8. ROS assay
Cells were incubated with 10 nM 20,70-dichloroﬂuorescein
diacetate (DCF-DA; Molecular Probes, Inc., Eugene, OR, USA) for
20 min to detect ROS, as described previously [8].2.9. Knockdown of proteins by small interfering RNA (siRNA)
The following human-speciﬁc siRNAs, synthesized as described
by the manufacturer (Genolution, Seoul, Korea), were used:
siPSMC5 #1, 50-CCA AGA ACAUCA AGG UUAUUU-30 (sense) and 50-
AUA ACC UUG AUG UUC UUG GUU-30 (antisense); siPSMC5 #2, 50-
GUG UGU AUC UCU CCA AUA AUU-30 (sense) and 50-UUA UUG GAG
AGA UAC ACA CUU-30 (antisense); siPSMC5 #3, 50-GUU AUC AUG
GCU ACU AAU AUU-30 (sense) and 50-UAU UAG UAG CCA UGA UAA
CUU-30 (antisense); and siMDM2, 50-AAU GCC UCA AUU CAC AUA
GAU UU-30 (sense) and 50-AUC UAU GUG AAU UGA GGC AUU UU-30
(antisense). A scrambled siRNA that showed no signiﬁcant ho-
mology to known gene sequences was used as a negative control.
For experiments, cells were transiently transfected with 20 nM
siPSMC5 #3 or siMDM2 in medium as described previously [8].2.10. Immunoﬂuorescence confocal microscopy
Immunoﬂuorescence staining for p21 (BD Pharmingen, San Jose,
CA, USA), pAKT (Ser473; Cell Signaling Technology Inc., Beverly,
MA, USA), and MDM2 (Santa Cruz Biotechnology Inc.) was per-
formed as described previously [8]. Cell nuclei were identiﬁed by
staining with 4.6-diamidino-2-phenylindole (DAPI).
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Western blot analyses were done as described previously [8]
using primary antibodies against cleaved-PARP (Asp214), cleaved
caspase-3, phospho-AKT (Ser473), AKT, and phopho-p53 (Ser15)
(Cell signaling Technology Inc.); p53, PSMC5 and MDM2 (Santa
Cruz Biotechnology Inc.); and p21 (BD Pharmingen). b-actin
(Sigma-Aldrich, St. Louis, MO, USA) was used as a loading control.
2.12. Statistical analysis
Cell culture experiments were repeated at least three times. All
data are expressed as means ± standard deviation. Statistical
evaluations were conducted using a one-way analysis of variance
(ANOVA). A P-value < 0.05 was considered signiﬁcant.
3. Results
3.1. Identiﬁcation of PSMC5 as a radiosensitivity biomarker in H460
cells
We established RR-H460 cells from radiosensitive parental
H460 cells by exposing them to 2 Gy radiation twice a week for 15
wk (data not shown) and analyzed the protein expression proﬁles
between these two cell lines using 2-D PAGE analysis. Among the
spots showing differential expression was that for PSMC5, which
was downregulated more than 2-fold in RR-H460 cells (Fig. 1A),
suggesting that it might be involved in radiosensitivity. ThisFig. 1. Identiﬁcation of PSMC5 as a radiosensitivity biomarker in H460 cancer cells. (A) 2D
cells. PSMC5 spots are marked by black arrows in each panel. (B) Magniﬁed view (top) an
by Western blotting. (C) MALDI-TOF/MS analysis of PSMC5. (D) Available datasets in the O
normal tissue (Case 1: threshold P-value ¼ 9.81  104, fold change  2; Case 2: threshold
lung cancer and their normal tissue counterparts stained with anti-PSMC5 antibody (scale ba
presented as box-and-whisker plots (*P < 0.05 compared with staining intensity of normadecrease is shownmore clearly inmagniﬁed images of PSMC5 spots
in gel images of parental H460 and RR-H460 cells, and was
conﬁrmed by Western blot analysis (Fig. 1B). The identity of this
spot as PSMC5 was determined by MALDI-TOF mass spectrometry
analysis, with excellent peptide coverage and a signiﬁcant MASCOT
score (Fig. 1C).
We also examined the correlation between PSMC5 expression
and lung cancer severity using the human genetic dataset analysis
tool, Oncomine. PSMC5 mRNA levels were signiﬁcantly lower in
lung carcinoid tumors (Fig. 1D, left) and lung adenocarcinoma tu-
mors (Fig. 1D, right) compared with normal lung tissue, suggesting
that PSMC5 functions as a tumor-suppressor. Consistent with
Oncomine data, in vivo evidence from tissuemicroarrays containing
lung cancers and their normal tissue counterparts showed that
PSMC5 expression was downregulated in lung cancer tissue
compared with their normal tissue counterparts (Fig. 1E). These
results suggest that PSMC5 knockdown could play a pivotal role in
acquisition of the radioresistance phenotype and tumorigenesis of
H460 cells.3.2. PSMC5 knockdown inhibits radiation-induced apoptosis of
H460 cells
To examinewhether PSMC5 plays a pivotal role in the regulation
of radiation-induced cell death, we transfected H460 cells with
siRNA to knock down endogenous PSMC5. As shown in Fig. 2A, all
three siRNAs markedly decreased PSMC5 protein and transcript
levels: qRT-PCR results showed that the most effective was siRNA-gel analysis of differentially expressed proteins between parental H460 and RR-H460
d expression level (bottom) of PSMC5 shown in A. Expression level was determined
ncomine database were queried for PSMC5 expression with respect to cancer versus
P-value ¼ 0.019, fold change  2). (E) Representative microscopic images of sections of
r: 1 mm). Staining intensity was scored as described in Materials and Methods; data are
l tissues).
Fig. 2. PSMC5 knockdown inhibits radiation-induced apoptosis of H460 cells. (A) H460 cells were transfected with 20 nM control siRNA (siCON) or three PSMC5 siRNAs (siPSMC5)
for 48 h. Protein and transcript levels of PSMC5 were determined by Western blotting (top) and conventional PCR (middle; loading control: GAPDH), respectively. qRT-PCR data
(bottom) are expressed as means ± SD (**P < 0.005 compared with untransfected control). (BeD) H460 cells were transfected with 20 nM siCON or PSMC5 siRNA #3 for 5 h and then
treated without or with 10 Gy radiation for an additional 48 h. Morphological changes were observed by light microscopy. Scale bars: 0.1 mm (B). Cell death was determined by FACS
analysis; data are expressed as means ± SD (**P < 0.005 compared with cells treated with radiation alone) (C). Protein levels of PSMC5 and two apoptosis markers were determined
by Western blotting (D). (E) H460 cells were transfected with 20 nM siCON or PSMC5 siRNA #3 for 24 h and then treated with single doses of radiation (0e6 Gy). Representative
images of colony formation at 14 d after radiation treatment, visualized by trypan blue staining, are shown.
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control siRNA. An assessment of cell morphology by light micro-
scopy revealed that treatment of H460 cells with 10 Gy radiation
very effectively induced cell death, an effect that was markedly
inhibited by PSMC5 knockdown (Fig. 2B). The death rate in H460
cells treatedwith radiation alonewas approximately 37% compared
to approximately 18% in PSMC5-transfected, radiation-treated
H460 cells, as determined by ﬂuorescence-activated cell sorting
(FACS) analysis (Fig. 2C). Consistent with FACS and microscopy re-
sults, the levels of cleaved-PARP and active caspase-3, two standard
apoptosis markers, were markedly increased in radiation-treated
H460 cells; these effects too were completely inhibited by PSMC5
depletion (Fig. 2D). Clonogenic survival assays showed that PSMC5-
depleted H460 cells displayed a more radioresistant phenotype
than control cells in response to a single dose of radiation ranging
from 0 to 6 Gy (Fig. 2E). Therefore, our results suggest that PSMC5
acts as a radiosensitive molecular target that mediates radiation-
induced cytotoxicity of H460 cells.
3.3. PSMC5 knockdown inhibits ROS generation and p21 protein
expression induced by radiation treatment in H460 cells
To determine whether PSMC5 is associated with the generation
of ROS, an important effector of radiation-induced apoptosis, we
transfected H460 cells with siRNA to knock down endogenous
PSMC5 and measured ROS levels by monitoring ﬂuorescence of the
ROS indicator, DCF-DA. Depletion of PSMC5 had little effect on ROS
levels in H460 cells in the absence of radiation exposure, but
signiﬁcantly suppressed the marked increase in ROS levels induced
by 6 Gy radiation treatment, as determined by cell staining
(Fig. 3A). FACS analysis showed that ROS levels were increased by
approximately 2.6-fold in radiation-treated H460 cells and werereduced by approximately 1.4-fold in PSMC5-knockdown H460
cells compared to nonirradiated cells (Fig. 3B), indicating that
PSMC5 positively regulates radiation-induced ROS generation. We
further tested whether ROS production is associated with levels of
the ROS-inducing apoptosis regulators, p53 and p21. Interestingly,
we found that silencing of PSMC5 alone markedly decreased p53
and p21 protein levels in H460 cells (Fig. 3C, left) without changing
their transcript levels (Fig. 3C, right), suggesting regulation of
protein stability. As expected, exposure of H460 cells to radiation
induced a time-dependent activation (phosphorylation) of p53 and
induction of p53 and p21 protein levels without altering PSMC5
protein level (Fig. 3D). However, radiation-induced p53 and p21
protein levels, which peaked 6 and 12 h after radiation treatment,
respectively (Fig. 3E), were markedly reduced by PSMC5 depletion.
p21 transcript levels were did not changed by PSMC5 knockdown,
as determined by conventional PCR (Fig. 3F, top) and qRT-PCR
(Fig. 3C, bottom); radiation-induced increases in p53 transcript
levels were similarly unaffected by PSMC5 knockdown (data not
shown). We next tested p21 protein localization, because it has
been shown that this is important for the control of cell survival. As
shown in Fig. 3G, p21 proteinwas mainly localized in the nucleus of
control H460 cells and was not redistributed by stimulation with
radiation and/or PSMC5 knockdown, although expression levels
were changed, consistent with the results of Western blot analyses.
Taken together, our data suggest that PSMC5 signaling is essential
for promoting cell death in radiation-treated H460 cells.
3.4. Downregulation of p21 protein in H460 cells by PSMC5
depletion is attributable to stabilization of AKT and MDM2
Because MDM2 activation by phosphoinositide 3-kinase (PI3K)/
AKT signaling acts as a negative regulator of p21 degradation in a
Fig. 3. PSMC5 knockdown inhibits ROS generation and radiation-induced expression of p53 and p21 protein in H460 cells. (A and B) H460 cells were transfected with 20 nM control
siRNA (siCON) or PSMC5 siRNA #3 (siPSMC5) for 24 h and then treated without or with 6 Gy radiation for an additional 24 h. Intracellular ROS levels were determined by ﬂuo-
rescence confocal microscopy (A; scale bar: 1 mm) and analyzed by FACS using 10 mM DCF-DA (B). (C) H460 cells were transfected with 20 nM siCON or PSMC5 siRNA #3 for 48 h.
Protein (left) and transcript (right) levels of PSMC5, p53, and p21 were determined by Western blotting and conventional PCR (loading control: GAPDH), respectively. (D) H460 cells
were treated with 6 Gy radiation for the indicated times. Protein levels of PSMC5, p53 and p21, and phosphorylation levels of p53 (pp53) were determined by Western blotting. (E)
H460 cells were transfected as in A and then treated without or with 6 Gy radiation for an additional 6 or 12 h. Protein levels of PSMC5, p53, and p21 were determined by Western
blotting. (F and G) H460 cells were transfected as in A and then treated without or with 6 Gy radiation for an additional 12 h. The presence of p21 transcripts was monitored by
conventional PCR (F, top; loading control: GAPDH), and p21 mRNA levels were determined by qRT-PCR (F, bottom). qRT-PCR data are expressed as means ± SD (x denotes no
signiﬁcance compared with cells treated with radiation alone). p21 localization was visualized by confocal microscopy; representative images are shown (G). Scale bar: 1 mm.
J.-H. Yim et al. / Biochemical and Biophysical Research Communications 469 (2016) 94e10098p53-independent manner [11,12], we examined whether the AKT-
MDM2 pathway is involved in PSMC5-depletion-mediated down-
regulation of p21 protein. Notably, we found that PSMC5 knock-
down led to induction of AKT phosphorylation at Ser473 in H460
cells without changing basal AKT expression levels, consistent with
the observed upregulation of MDM2 protein (Fig. 4A, left) and
mRNA (Fig. 4A, right) levels, the latter of which were increased by
approximately 1.8-fold in PSMC5-knockdown H460 cells compared
to control cells. MDM2 protein was predominantly localized to the
nucleus in control H460 cells and its distributionwas unaffected by
PSMC5 depletion (Fig. 4B, top). Interestingly, phosphorylated AKT
was located in both cytosol and nucleus in control H460 cells, but
its nuclear localization was increased in PSMC5-knockdown H460
cells (Fig. 4B, bottom), presumably reﬂecting the association of AKT
activation with MDM2 transcript levels. Furthermore, exposure of
H460 cells to radiation reduced AKT phosphorylation and MDM2
protein levels compared with control cells, affects that were
markedly attenuated by PSMC5 depletion (Fig. 4C). Finally, we
conﬁrmed the association of PSMC5-mediated p21 regulation with
the AKT-MDM2 pathway using an AKT or MDM2 loss-of-function
approach. Notably, the level of p21 protein, which was signiﬁ-
cantly reduced in association with a striking increase in activating
AKT phosphorylation in radiation-treated, PSMC5-knockdown
H460 cells, was completely recovered by treatment withtriciribine, a speciﬁc inhibitor of AKT (Fig. 4D), indicating that p21
protein is a downstream target of the AKT pathway. The reduction
of p21 levels in PSMC5-knockdown H460 cells was also restored by
silencing of MDM2, consistent with the fact that MDM2 is an up-
stream regulator of p21 protein degradation (Fig. 4E). Taken
together, our data indicate that acquisition of a radioresistant
phenotype in PSMC5-depleted H460 cells is attributable to p21
degradation through AKT-dependent MDM2 stabilization.
4. Discussion
We detected approximately 2000 differentially expressed pro-
teins between radiosensitive parental H460 cells and their radio-
resistant derivative. A total of 23 protein spots were downregulated
in radioresistant H460 cells, eight of which were altered by more
than 2-fold, including PSMC5, a regulatory ATPase subunit of the
26S proteasome. Because the 26S proteasome system is involved in
the ATP-dependent degradation of ubiquitinated proteins, PSMC5
may play a crucial role in maintaining cellular proteome homeo-
stasis in a variety of situations [3]. This subunit is now known to
play roles in controlling transcriptional regulation [4,5], but PSMC5
modulation as a contributor to tumor resistance and progression
has not been investigated. The present study provides the ﬁrst
evidence for the novel function of PSMC5 in the susceptibility of
Fig. 4. PSMC5 knockdown induces degradation of p21 protein through activation of AKT-MDM2 in H460 cells. (A and B) H460 cells were transfected with 20 nM siCON (siCON) or
PSMC5 siRNA #3 (siPSMC5) for 48 h. Protein levels of PSMC5, AKT and MDM2, and phosphorylation levels of AKT (pAKT) were determined by Western blotting (A, left). MDM2
transcript levels were determined by qRT-PCR (A, right); data are expressed as means ± SD (*P < 0.05 compared with untransfected control). MDM2 and phosphorylated-AKT
localization was visualized by confocal microscopy; representative images are shown (B; scale bar: 0.5 mm). (C) H460 cells were transfected with 20 nM siCON or PSMC5
siRNA #3 for 24 h and then treated without or with 6 Gy radiation for an additional 24 h. Protein levels of PSMC5, AKT and MDM2, and phosphorylation levels of AKT were detected
by Western blotting. (D) H460 cells were transfected as in C and then treated without or with 6 Gy radiation in the absence (Veh) or presence (Tri) of 10 mM triciribine for an
additional 24 h. Protein levels of PSMC5, AKT and p21, and phosphorylation levels of AKT were detected by Western blotting. (E) H460 cells were transfected with 20 nM siCON or
PSMC5 siRNA #3 and/or 20 nM MDM2 siRNA, as indicated, for 48 h. Protein levels of PSMC5, MDM2, and p21 were determined by Western blotting.
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Erina et al. provided evidence that constitutively reduced 26S
proteasome activity increases self-renewal capacity in glioma and
breast cancer cells, and is thus associated with clinical resistance to
radiation therapy [13]. Intrinsically low 26S proteasome activity,
which is responsible for the resistance to proteasome inhibitors and
radiation treatment, has been shown to contribute to the failure of
clinical trials in advanced prostate cancer [14]. Consistent with
these observations, we found that loss of PSMC5 function inhibits
radiation-induced cell death in H460 cancer cells (Fig. 2). Protea-
some activity plays a fundamental role in many cellular processes,
including cell-cycle regulation, gene expression and cell differen-
tiation, and has therefore become an important target for anti-
cancer therapy. Proteasome inhibitors have been suggested as
promising new agents against solid tumors, but initial results from
clinical trials have shown little antitumor activityda failure
attributable to cancer cells with a low-proteasome-activity
phenotype [14]. In keeping with this, our ﬁndings suggest the
additional possibility that PSMC5 plays an important role as a
radiosensitizing factor in lung cancer cells; thus, its low activity is
responsible for the radioresistance of RR-H460 NSCLC cells.Because it is unknown why PSMC5 depletion promotes resis-
tance to radiation in H460 cells, it will be important to investigate
how PSMC5 knockdown contributes to radiation-induced changes
in cell functions, such as proliferation and apoptosis. Our demon-
stration of PSMC5 knockdown-dependent AKT phosphorylation is
in accord with a previous report showing an association of AKT
activationwith the radioresistance phenotypes of different cancers,
including colon, prostate, and brain cancer [15]. In addition, the
MDM2 oncoprotein is overexpressed in many human malignancies
and its nuclear localization is dependent on its interaction with
activated AKT [11,15]. This cascade stimulates formation of a com-
plex of MDM2 with p21 and p53 that promotes ubiquitin-
independent or -dependent degradation of p21 and p53 [12,16].
In this study, AKT, activated by PSMC5 depletion, was predomi-
nantly translocated into the nucleus, enhancing the nuclear accu-
mulation of MDM2 protein. Furthermore, inhibition of AKT
signaling or MDM2 expression strongly restored p21 protein levels
that were decreased by PSMC5 knockdown in H460 cells (Fig. 4),
indicating that the AKT-MDM2 pathway is involved in the radio-
resistance phenotype as a negative regulator of p21. Intracellular
ROS are important mediators of apoptosis and their regulation was
J.-H. Yim et al. / Biochemical and Biophysical Research Communications 469 (2016) 94e100100dependent on the levels of p21 expression (Fig. 3), suggesting that
p21-mediated ROS production could also participate in cell fate
decisions.
In conclusion, PSMC5 depletion modulated the radiosensitivity
of H460 NSCLC cells by activating AKT-MDM2 signaling and, in turn,
triggering a decrease in p53 and p21 activity, thereby contributing
to acquisition of radioresistance. Therefore, PSMC5 status could
serve as a prognostic indicator for radiotherapy, and restoring
PSMC5 activity might represent an alternative strategy for treating
cancer when serious resistance to radiotherapy is present.
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